International Journal of Infectious Diseases (Jun 2021)
Isoniazid-monoresistant tuberculosis in France: Risk factors, treatment outcomes and adverse events
- Marwa Bachir,
- Lorenzo Guglielmetti,
- Simone Tunesi,
- Typhaine Billard-Pomares,
- Sheila Chiesi,
- Jérémy Jaffré,
- Hugo Langris,
- Valérie Pourcher,
- Frédéric Schramm,
- Nadine Lemaître,
- Jérôme Robert,
- O. Bouchaud,
- T. Billard-Pomares,
- E. Carbonnelle,
- F. Mechaï,
- H. Nunes,
- M. Pellan,
- A.-S. Morin,
- C. Dumesnil,
- J. Dumoulin,
- A.-L. Roux,
- M. Jachym,
- D. le Du,
- D. Marigot-Outtandy,
- S. Abgrall,
- V. Chambrin,
- C. Guillet,
- B. Fantin,
- A. Galy,
- J.-W. Decousser,
- J.D. Lelièvre,
- S. Gallien,
- B. Nebbad-Lechani,
- L. Deconinck,
- S. Bulifon,
- N. Fortineau,
- B. Wyplosz,
- F. Cohen,
- N. Lemaitre,
- B. Crestani,
- N. Grall,
- C. Pierre-Audigier,
- C. Rioux,
- Y. Yazdanpanah,
- C. Le Jeunne,
- P. Morand,
- N. Roche,
- J. Pavie,
- P. Loulergue,
- V. Delcey,
- E. Lecorché,
- A.-L. Munier,
- F. Mougari,
- P. Sellier,
- E. Bille,
- A. Ferroni,
- R. Guéry,
- A. Hummel,
- J. Lourenco,
- A. Aubry,
- I. Bonnet,
- E. Caumes,
- C. Londner,
- F. Morel,
- K. Lacombe,
- V. Lalande,
- J.-L. Meynard,
- N. Veziris,
- N. De Castro,
- B. Denis,
- M. Lafaurie,
- J.-M. Molina,
- A. Canestri,
- L. Lassel,
- G. Pialoux,
- C. Verdet,
- A.-L. Nardi,
- M. Gominet,
- E. Catherinot
Affiliations
- Marwa Bachir
- Centre d’Immunologie et des Maladies Infectieuses, Sorbonne – Université, INSERM, (U1135 – E2), Paris, France; Corresponding author at: 4 rue de la Chine, 75020 Paris, France.
- Lorenzo Guglielmetti
- Centre d’Immunologie et des Maladies Infectieuses, Sorbonne – Université, INSERM, (U1135 – E2), Paris, France; Centre National de Référence des Mycobactéries et de la Résistance des Mycobactéries aux Antituberculeux, Bactériologie-Hygiène, AP-HP, Sorbonne Université, Site Pitié, Paris, France
- Simone Tunesi
- Service de Médecine Interne, Hôpital Jean Verdier, AP-HP, Université Paris 13, Bondy, France
- Typhaine Billard-Pomares
- Laboratoire de Microbiologie Clinique, CHU Avicenne, AP-HP, Université Paris 13, Bobigny, France
- Sheila Chiesi
- Centre d’Immunologie et des Maladies Infectieuses, Sorbonne – Université, INSERM, (U1135 – E2), Paris, France
- Jérémy Jaffré
- Centre National de Référence des Mycobactéries et de la Résistance des Mycobactéries aux Antituberculeux, Bactériologie-Hygiène, AP-HP, Sorbonne Université, Site Pitié, Paris, France
- Hugo Langris
- Normandie Université, UNICAEN, CHU de Caen Normandie, Service de Bactériologie, 14000 Caen, France
- Valérie Pourcher
- Service des Maladies Infectieuses et Tropicales, AP-HP, Sorbonne Université, Site Pitié, Paris, France; Institut Pierre Louis d’Epidémiologie et de Santé Publique (iPLESP), Inserm UMR_S 1136, Paris, France
- Frédéric Schramm
- Laboratoire de Bactériologie, CHU de Strasbourg, Strasbourg, France
- Nadine Lemaître
- Service de Bactériologie-Hygiène, Centre de Biologie-Humaine, CHU d’Amiens, Amiens, France
- Jérôme Robert
- Centre d’Immunologie et des Maladies Infectieuses, Sorbonne – Université, INSERM, (U1135 – E2), Paris, France; Centre National de Référence des Mycobactéries et de la Résistance des Mycobactéries aux Antituberculeux, Bactériologie-Hygiène, AP-HP, Sorbonne Université, Site Pitié, Paris, France
- O. Bouchaud
- T. Billard-Pomares
- E. Carbonnelle
- F. Mechaï
- H. Nunes
- M. Pellan
- A.-S. Morin
- C. Dumesnil
- J. Dumoulin
- A.-L. Roux
- M. Jachym
- D. le Du
- D. Marigot-Outtandy
- S. Abgrall
- V. Chambrin
- C. Guillet
- B. Fantin
- A. Galy
- J.-W. Decousser
- J.D. Lelièvre
- S. Gallien
- B. Nebbad-Lechani
- L. Deconinck
- S. Bulifon
- N. Fortineau
- B. Wyplosz
- F. Cohen
- N. Lemaitre
- B. Crestani
- N. Grall
- C. Pierre-Audigier
- C. Rioux
- Y. Yazdanpanah
- C. Le Jeunne
- P. Morand
- N. Roche
- J. Pavie
- P. Loulergue
- V. Delcey
- E. Lecorché
- A.-L. Munier
- F. Mougari
- P. Sellier
- E. Bille
- A. Ferroni
- R. Guéry
- A. Hummel
- J. Lourenco
- A. Aubry
- I. Bonnet
- E. Caumes
- C. Londner
- F. Morel
- K. Lacombe
- V. Lalande
- J.-L. Meynard
- N. Veziris
- N. De Castro
- B. Denis
- M. Lafaurie
- J.-M. Molina
- A. Canestri
- L. Lassel
- G. Pialoux
- C. Verdet
- A.-L. Nardi
- M. Gominet
- E. Catherinot
- Journal volume & issue
-
Vol. 107
pp. 86 – 91
Abstract
Objectives: Isoniazid-monoresistant tuberculosis (HR-TB) is the most prevalent form of drug-resistant TB worldwide and in France and is associated with poorer treatment outcomes compared with drug-susceptible TB (DS-TB). The objective of this study was to determine the characteristics of HR-TB patients in France and to compare outcomes and safety of treatment for HR-TB and DS-TB. Methods: We performed a case-control multicenter study to identify risk factors associated with HR-TB and compare treatment outcomes and safety between HR-TB patients and DS-TB patients. Results: Characteristics of 99 HR-TB patients diagnosed and treated in the university hospitals of Paris, Lille, Caen and Strasbourg were compared with 99 DS-TB patients. Female sex (OR = 2.2; 1.0–4.7), birth in the West-Pacific World Health Organization region (OR = 4.6; 1.1–18.7) and resistance to streptomycin (OR = 77.5; 10.1–594.4) were found to be independently associated with HR-TB. Rates of treatment success did not differ significantly between HR-TB and DS-TB. Conclusions: Factors associated with HR-TB are not significant enough to efficiently screen TB patients at risk of HR-TB. The systematic implementation of rapid molecular testing on clinical samples remains the only effective way to make the early diagnosis of HR-TB and adapt treatment.
